Prenatal treatment of congenital adrenal hyperplasia. The United States experience.

Abstract

Based on the author's experience, prenatal diagnosis and treatment of 21-hydroxylase deficiency is safe and effective in significantly reducing or eliminating virilization in the affected female, and the same outcome seems to be true in the treatment of 11 beta-hydroxylase deficiency. Prenatal treatment spares the newborn female the consequences of genital ambiguity, genital surgery, sex misassignment, and gender confusion. Of the monogenic disorders, steroid 21- and 11 beta-hydroxylase deficiency are two of the few in which prenatal treatment is effective and influences postnatal life.

• Authors: M I New
• Journal: Endocrinology and metabolism clinics of North America (Endocrinol Metab Clin North Am) Vol. 30 Issue 1 Pg. 1-13 (Mar 2001) ISSN: 0889-8529 [Print] United States
• PMID: 11344929 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Glucocorticoids
• Steroid 21-Hydroxylase
• Steroid 11-beta-Hydroxylase

Topics

• Adrenal Hyperplasia, Congenital (diagnosis, drug therapy, enzymology)
• Female
• Fetal Diseases (drug therapy)
• Glucocorticoids (administration & dosage, adverse effects, therapeutic use)
• Humans
• Male
• Mutation
• Pregnancy
• Prenatal Diagnosis
• Steroid 11-beta-Hydroxylase (genetics)
• Steroid 21-Hydroxylase (genetics)
• United States